Fulcrum Therapeutics Inc (NASDAQ:FULC) price on Thursday, July 03, fall -0.14% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $6.92.
A look at the stock’s price movement, the close in the last trading session was $6.93, moving within a range at $6.65 and $6.95. The beta value (5-Year monthly) was 2.42. Turning to its 52-week performance, $10.13 and $2.32 were the 52-week high and 52-week low respectively. Overall, FULC moved -1.63% over the past month.
Fulcrum Therapeutics Inc’s market cap currently stands at around $373.54 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-01.
Turning to the stock’s technical picture we see that short term indicators suggest on average that FULC is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
13 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 4 analyst(s) rate the stock as a Hold, 9 recommend FULC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
FULC’s current price about -0.43% and 12.09% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 54.71, while 7-day volatility ratio is 8.31% and 6.77% in the 30-day chart. Further, Fulcrum Therapeutics Inc (FULC) has a beta value of 2.48. Analysts have given the company’s stock an average 52-week price target of $10.5, forecast between a low of $9 and high of $12. Looking at the price targets, the low is -30.06% off current price level while to achieve the yearly target high, price needs to move -73.41%. Nonetheless, investors will most likely welcome a -51.73% jump to $10.5 which is the analysts’ median price.
If we refocus on Fulcrum Therapeutics Inc (NASDAQ:FULC), historical trading data shows that trading volumes averaged 0.64 over the past 10 days and 603.20K over the past 3 months. The company’s latest data on shares outstanding shows there are 53.98 million shares.
The 11.36% of Fulcrum Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 85.60% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 5.82 million on 2025-06-13, giving us a short ratio of 10.67. The data shows that as of 2025-06-13 short interest in Fulcrum Therapeutics Inc (FULC) stood at 1558.0 of shares outstanding, with shares short rising to 4.93 million registered in 2025-05-15. Current price change has pushed the stock 9.67% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the FULC stock continues to rise going into the next quarter.
